Matthew Roller, MD
Neurology · Grand Forks, NDNPI 1033283379
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $300 of the $345 with a category attached, or 87.0%. It is spread thinly across 10 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $166 and has fallen 64.8% since, to $59 in 2024. That places this record below the midpoint for neurology clinicians in ND, where the typical reported total is $432.
Across 20 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$81
- AbbVie$54
- Bristol Myers Squibb$39
- Kyowa Kirin, Inc.$37
- Biohaven Pharmaceuticals, Inc.$37
- AstraZeneca$30
- plus $69 from 4 others
Across 1 payment — averaging $411.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$412
What the payments were for
- Food & beverage$30087%
- Education$4513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 3 | $81 |
| AbbVie(2 entities) | 3 | $54 |
| Bristol Myers Squibb | 3 | $39 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 3 | $37 |
| AstraZeneca | 2 | $30 |
| Biogen | 1 | $21 |
| Amgen | 1 | $20 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Merz North America, Inc. | 1 | $12 |
How this compares
$345 in reported general payments places this provider in the 45th percentile of 39 neurology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 32 | $271,881 |
| GilenyaFingolimod Hcl | 12 | $121,836 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $115,110 |
| Dimethyl Fumarate | 41 | $71,023 |
| Aimovig AutoinjectorErenumab-Aooe | 86 | $68,485 |
| KeppraLevetiracetam | 17 | $42,770 |
| Nurtec OdtRimegepant Sulfate | 33 | $33,656 |
| TopamaxTopiramate | 25 | $32,246 |
| TrileptalOxcarbazepine | 11 | $25,555 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 513 | $19,263 |
| Dalfampridine ErDalfampridine | 17 | $18,835 |
| LamictalLamotrigine | 20 | $18,428 |
| Lacosamide | 62 | $15,110 |
| UbrelvyUbrogepant | 15 | $15,079 |
| EliquisApixaban | 32 | $14,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $21 | $271,88132 claims |
| AbbVieUbrelvy | $54 | $15,07915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 39 neurology providers in North Dakota.
Other neurology in Grand Forks
- James MilesGrand Forks$3K
- Rebecca NovacekGrand Forks$554
- Cory EdwardsGrand Forks$523
- Tanya HarlowFargo$73K
- Susan ScarberryFargo$67K
- Sarah KendroudFargo$42K
- Scott BellistonFargo$9K
- Jess MillerBismarck$2K
- Gary MillerFargo$2K
- Ralph DunniganBismarck$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.